سعر Quitcool xr 50mg 30 ext. rel. f.c. tabs 2025

Quitcool xr 50mg 30 ext. rel. f.c. tabs: quetiapine 50 mg extended-release film-coated tablets, an atypical antipsychotic marketed in Egypt by Hikma Pharma.

• Schizophrenia (acute and maintenance)Population: Adults; adolescents 13-17 years (acute)DailyMed (U.S. National Library of Medicine)
• Bipolar I disorder manic or mixed episodes (monotherapy or adjunct)Population: Adults; children and adolescents 10-17 years (manic, monotherapy)DailyMed (U.S. National Library of Medicine)
• Bipolar disorder depressive episodesPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Most common in adults: somnolence, dry mouth, dizziness, constipation, asthenia, abdominal pain, postural hypotension, pharyngitis, weight gain, lethargy, ALT increased, dyspepsia. Children/adolescents: somnolence, dizziness, fatigue, increased appetite, nausea, vomiting, dry mouth, tachycardia, weight increased.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to quetiapine or any excipient; anaphylactic reactions have been reported.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: increased mortality in elderly patients with dementia-related psychosis; not approved for this use.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning: suicidal thoughts and behaviours in children, adolescents and young adults; monitor for clinical worsening and suicidality.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Metabolic changes (hyperglycaemia/diabetes, dyslipidaemia, weight gain), neuroleptic malignant syndrome, tardive dyskinesia, orthostatic hypotension and falls, leukopenia/neutropenia/agranulocytosis, QT prolongation (avoid with other QT-prolonging drugs), seizures, hypothyroidism, hyperprolactinaemia, cognitive/motor impairment, cataracts, dysphagia, anticholinergic effects and discontinuation symptoms; gradual withdrawal advised.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, ritonavir, nefazodone)Reduce quetiapine dose to one-sixth; increase 6-fold when the inhibitor is stopped.DailyMed (U.S. National Library of Medicine)
• Strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampin, St John's wort)Increase quetiapine dose up to 5-fold with chronic (>7-14 days) inducer use; reduce to original dose within 7-14 days of stopping the inducer.DailyMed (U.S. National Library of Medicine)
• Alcohol and other CNS depressantsQuetiapine potentiates cognitive and motor effects of alcohol; limit alcohol.DailyMed (U.S. National Library of Medicine)

• Available epidemiologic data have not established a drug-associated risk of major birth defects or miscarriage; risks of untreated maternal illness should be considered.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Present in human milk at a relative infant dose below 1%; no consistent adverse effects reported in breastfed infants; weigh benefits and risks.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Quetiapine: Mechanism unknown; efficacy may be mediated through combined dopamine D2 and serotonin 5-HT2A receptor antagonism (US label).